tbuckley/cabot-search huggingface dataset:
Secondary AML After a History of Myelodysplastic Syndrome Is An Independent Adverse Prognostic Factor for Achievement of Complete Remission, Relapse-Free and Overall Survival. An Analysis of 2,819 Adult Patients with Newly Diagnosed AML Enrolled On Seven AMLSG Treatment Trials.
Authors: Sabine Kayser, Konstanze Doehner, Juergen Krauter, Heinz A. Horst, Marie von Lilienfeld-Toal, Ulrich Germing, Katharina Goetze, Michael Pfreundschuh, Walter Fiedler, Daniela Spaeth, Silja Groner, Brigitte Schlegelberger, Gudrun Goehring, Arnold Ganser, Hartmut Doehner, Richard F. Schlenk
Journal: Blood (2009)
Frequent Mutation of the Polycomb-Associated Gene ASXL1 in the Myelodysplastic Syndromes and in Acute Myeloid Leukaemia.
Authors: Jacqueline Boultwood, Janet Perry, Andrea Pellagatti, Aristoteles Giagounidis, Luca Malcovati, Matteo G Della Porta, Martin Jädersten, Sally Killick, Eva Hellström-Lindberg, Mario Cazzola, James S Wainscoat
Journal: Blood (2009)
Current management of borderline ovarian tumors: A multicenter survey of 323 clinics in Germany, on behalf of the North-Eastern German Society of Gynecological Oncology (NOGGO)
Authors: R. Chekerov, A. Coumbos, J. Sehouli, D. Schaedel, G. Oskay-Oezcelik, W. Lichtenegger, W. Kuehn
Journal: Journal of Clinical Oncology (2009)

e16568 Background: The aim of this survey was to analyze the standard of care in diagnostic, surgery, chemotherapy and aftercare management of patients with Borderline tumor of the ovary (BOT) in Germany. Methods: A structured questionnaire comprising different dimensions of treatment of BOT was sent to all 1,114 gynecological departments in Germany. The questionnaire could be returned anonymously. Results: The overall response rate was 29.0% (323 departments). The most departments were on secondary care (71.8%), tertiary care (23.2%) or university hospital (5.0%) level. The most clinicians performed not more than 5 BOT operations (89.2%) per year. 93.2% of the gynecological departments used additional preoperative diagnostic procedures to the classical bimanual examination and vaginal ultrasound in a case of unclear ovarian tumor: CA-125 or CEA detection (95%), CT-scan (76%), Doppler ultrasound (66%), MRI (36%), or PET-CT (1.7%) techniques. In university hospitals (87%), tertiary care (80%), secondary care (68%) and most of the general practitioners’ hospitals (64%) a regular fresh frozen section was the intraoperative diagnostic standard. For diagnosis of BOT mostly laparotomy (48%) and laparoscopy (15%) were performed, whereas 19% used a diagnostic laparoscopy, followed by laparotomy for completion in a second intervention or switch from laparoscopy to laparotomy in the primary surgical session (18%). In young women with desire to preserve fertility clinicians performed much seldom unilateral salpingo-oophorectomy (92%) and only in 53% biopsies of the contra lateral ovary and in 67% peritoneal biopsies. Generally biopsies of the contra lateral ovary were performed in 4% to 53% of all patients. Chemotherapy was the second therapy option (64%) after surgery (97%) for BOT, mostly favored in “high-risk” patients with tumor residual, micro invasion or invasive implants. Conclusions: These data demonstrate a high clinical unsureness in the clinical management of borderline tumors of the ovary. No significant financial relationships to disclose.
Efficacy of busulfan-melphalan high dose chemotherapy consolidation (BuMel) in localized high-risk Ewing sarcoma (ES): Results of EURO-EWING 99-R2 randomized trial (EE99R2Loc).
Authors: Jeremy Whelan, Marie-Cecile Le Deley, Uta Dirksen, Ian Robert Judson, Douglas S. Hawkins, Hendrik Van Den Berg, Ruth Ladenstein, Jarmila Kruseova, Andreas Ranft, Susanne Amler, Nathalie Gaspar, Valerie Laurence, Gwenael Le Teuff, Perrine Marec-Berard, Bernadette Brennan, Keith Wheatley, Bruce Morland, Sandrine Marreaud, Heribert Juergens, Odile Oberlin
Journal: Journal of Clinical Oncology (2016)

11000 Background: EE99R2Loc (ISRCTN61438620) was conducted in 12 countries, by 4 cooperative groups: GPOH, SFCE/GSF, UK-CCLG, and EORTC. It evaluated effects on event-free (EFS, main endpoint) and overall survival (OS) of BuMel compared to standard chemotherapy in ES presenting with localized disease and either a poor histologic response to induction chemotherapy or large tumor volume ( > 200ml) unresected or initially resected. Methods: Eligible pts were aged < 50, received 6 VIDE courses (vincristine, ifosfamide, doxorubicin, etoposide) and 1 VAI (vincristine, actinomycin-D, ifosfamide) before randomization to BuMel with stem cell rescue or VAI x 7 courses. The estimate of hazard ratio (HR) and the p-value were corrected for the 4 previous interim analyses by the Inverse Normal Method. Results: Between 2000 and 2013, from 477 pts classified as high-risk pts, 216 pts (median age, 17 yrs) were randomized to VAI (107) or BuMel (109). Some pts requiring radiation therapy (RT) to the primary site were excluded to avoid excess organ toxicity from interaction between RT and Busulfan. 80% entered the trial because of poor histologic response after chemotherapy alone. Median follow up is 8.0 yrs, with only 3 pts lost to follow up before 3 yrs. Overall, 3yr EFS is 60.0% and OS, 73.9%. In an intention to treat analysis, the risk of an event was significantly decreased by BuMel compared to VAI: HR = 0.63 (95%CI, 0.42-0.94) p = .023 ; 3yr-EFS of 66.9% (57.6-75.0) vs. 53.1% (43.6-62.3). OS also favored BuMel, 77.8 vs. 69.9%, HR = 0.60 (0.39-0.92) p = .019. Results were consistent across subgroups, and in sensitivity analyses. Two pts died of BuMel-related toxicity and 1 after standard chemotherapy. Significantly more BuMel pts experienced severe acute toxicities, but these arose from a single high-dose course vs. multiple VAI courses. Conclusions: BuMel conferred improvement in EFS and OS with acceptable toxicity for pts with localized ES and poor histological response to chemotherapy or large tumor volume unresected or initially resected. It should be considered as a standard of care for this group of pts with localized high-risk ES and no contra-indication to BuMel. Clinical trial information: 61438620.
Abstract C26: Melanoma brain metastasis is facilitated by instigation of reactive astrogliosis
Authors: Hila Schwartz, Eran Blacher, Malak Amer, Nir Livneh, Anat Klein, Dikla Ben-Shushan, Shelly Soffer, Reuven Stein, Ronit Satchi-Fainaro, Viktor Umansky, Tobias Pukrop, Neta Erez
Journal: Cancer Research (2016)

Abstract Melanoma frequently metastasizes to the brain, resulting in dismal survival. A major obstacle for characterizing mechanisms of brain metastasis is the lack of tractable pre-clinical models that mimic the multi-stage process of brain metastasis. We established a novel model of spontaneous melanoma brain metastasis in immunocompetent mice. Aggressive local tumors are formed following orthotopic injection, and 3-4 months after surgical excision of the primary tumor, 50% of the mice develop brain macrometastases. By utilizing a unique ex-vivo modeling system, we detected brain micrometastases in 50-60% of the mice and quantified the metastatic load. Moreover, we show that the detection of melanoma transcripts in cerebrospinal fluid (CSF) is correlated with brain metastases. Interestingly, preliminary findings suggest that the melanoma-derived transcripts are found in exosomes. Astrocytes are glial cells that maintain brain homeostasis, and constitute a central part of the brain microenvironment. Reactive astrogliosis is the primary response of astrocytes to brain insult. While much data have accumulated on the contribution of astrogliosis to neurodegenerative diseases, the functional role of astrogliosis in promoting melanoma brain metastases is unknown. Utilizing our model we demonstrate early changes in the microenvironment and show that micrometastases are associated with activation of astrocytes and with hyperpermeability of the blood-brain-barrier. In-vitro, paracrine signaling by melanoma cells activated astrocytes to up-regulate a ‘wound healing program’ including Cxcl10 and Serpins. Reciprocally, astrocytes facilitated the invasion of melanoma cells and were necessary for primary outgrowth in 3D co-cultures. Finally, we show that intracranial co-injection of astrocytes with melanoma cells resulted in a 9 fold increase of tumor volume, and that the same gene-signature was up-regulated in astrocytes in-vivo. Studying spontaneous melanoma brain metastasis in a clinically relevant setting enables in-depth understating of the metastatic microenviromet which is the key to developing therapeutic approaches that may prevent brain metastatic relapse. Citation Format: Hila Schwartz, Eran Blacher, Malak Amer, Nir Livneh, Anat Klein, Dikla Ben-Shushan, Shelly Soffer, Reuven Stein, Ronit Satchi-Fainaro, Viktor Umansky, Tobias Pukrop, Neta Erez. Melanoma brain metastasis is facilitated by instigation of reactive astrogliosis. [abstract]. In: Proceedings of the AACR Special Conference: Function of Tumor Microenvironment in Cancer Progression; 2016 Jan 7–10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2016;76(15 Suppl):Abstract nr C26.
Course and prognosis of basaloid squamous cell carcinoma (BSCC) of the head and neck: A case-control study of 62 patients
Authors: C. A. Righini, C. Faure, S. Lantuejoul, K. Chahine, E. Soriano, E. Brambilla, M. Bolla, E. Reyt
Journal: Journal of Clinical Oncology (2008)

17002 Background: BSCC of the upper aero-digestive tract is a rare subtype of squamous cell carcinoma (SCC). Our objective was to evaluate the prognosis of BSCC as compared to the usual SCC in the largest series of cases. Methods: BSCCs (case group) and a matched group (control group) of patients diagnosed with poorly-to-well differentiated SCC were selected in a retrospective (1988–2005) case-control study. BSCCs were deliberately classified histologically into 3 groups depending on the percentage of basaloid component (1 = 10–39%/2 = 40–79%/3 = 80–100%), with a minimum of 10% of basaloid component required for that diagnosis. Fisher’s exact test, Kaplan-Meier method, log-rank test, and logistic regression tests were used for statistical analysis. Results: Sixty-two BSCCs (group 1 = 15/group 2 = 19/group 3 = 28) and 62 SCCs (40 well-16 moderately-and 6 poorly-differentiated) were included. Epidemiological characteristics and location of the tumors were similar for both groups (hypopharynx = 31/oropharynx and oral cavity = 19/larynx = 8/rhinopharynx = 1/cervical lymph nodes = 3). In each group, 32 patients presented with an advanced tumor stage, and 46 patients did not receive any prior treatment, whilst 16 were previoulsy treated (chemo and/or radiotherapy). However, in the BSCC group, distant metastases were 6 times higher and were the major cause (70%) of mortality. The overall, specific, and disease-free survival rates were statistically lower than in the SCC group (p<0,01), independently of the location, stage of the tumor, and previous treatment. No correlation was observed between the basaloid component percentage and the survival rates. The lymphovascular invasion (LI) significantly affected the survival rate in the BSCC group, but not in the SCC group (p< 0,01). A multivariate statistical analysis in the BSCC group showed that the LI was the main parameter influencing the survival (p< 0,001). Conclusions: BSCC has distinct histopathologic features and an aggressive course, justifying its consideration as a separate entity with poor prognosis. We suggest to systematically perform an exhaustive metastatic work-up at inclusion to rule out early distant metastasis and to include adjuvant chemotherapy in treatment protocols. No significant financial relationships to disclose.
There is no such thing as a simple ankle sprain: clinical commentary on the 2016 International Ankle Consortium position statement
Authors: C Niek van Dijk, Gwendolyn Vuurberg
Journal: British Journal of Sports Medicine (2016)

Lateral ankle sprains (LAS) have a high incidence and prevalence among a relatively young population. It is the most commonly incurred musculoskeletal trauma among athletes. The prevalence of LAS among the general population is also high. LAS is associated with a wide range of negative sequelae leading to a substantial healthcare burden and by consequence high societal costs. As such, LAS has a high socioeconomic impact.1 In the previous issue, the Executive Committee of the International Ankle Consortium presents a position paper with recommendations based on a consensus statement on the prevalence, impact and long-term consequences of LAS.2 ,3

The authors state that following a LAS injury, most patients do not receive ongoing supervised professional treatment for their injury.4 Acute injury-associated symptoms typically resolve in a short period of time. However, after an acute ankle sprain, as many as 70% of patients can develop long-lasting symptoms. These symptoms may include persistent ‘giving way’ of the ankle joint, a …
Consequences of different approaches to local treatment of Ewing’s sarcoma within an international randomised controlled trial: Analysis of EICESS-92
Authors: J. Whelan, A. McTiernan, C. Weston, C. Douglas, R. Grimer, A. Cassoni, M. Paulussen, H. Jurgens, A. Craft, I. Lewis
Journal: Journal of Clinical Oncology (2006)

9533 Background: Two national clinical trial groups (NCTG 1 and 2) together undertook a randomised trial (EICESS-92) which addressed chemotherapy treatment options for Ewing’s sarcoma (ES). No significant differences were found in analysis of the randomised trial questions. A significantly greater use of surgery, with or without radiotherapy, to achieve local tumour control was noted in NCTG 1. The influence on overall outcome was investigated. Methods: Univariate and multivariate analysis of the trial data set was undertaken. Patient characteristics, recognised prognostic factors for ES and treatment factors were all examined. Results: In total, 647 patients (pts) were randomised (NCTG 1: 437 pts; NCTG 2: 210 pts). There were no differences between groups in patient characteristics, disease factors or in chemotherapy received. Surgery of the primary tumour (74.6% v 51%) and pre-operative radiotherapy (44.6% v 2.9%) were more commonly used by NCTG1. Radiotherapy alone was more commonly used by NCTG 2 (39% v 19.5%). Five year overall survival (OS) for the whole cohort was 62.1% (95%CI: 58.3 to 66.0). Five year OS was 66.5% (95% CI 62.0–71.1) for NCTG 1 and 54.3% (95% CI 47.3–61.4) for NCTG 2 (p=0.009). OS was best for those selected for surgery alone and worst for those treated with radiotherapy alone (p &lt;0.001). OS was equivalent between groups for each modality of local treatment. Local recurrence rates for NCTG1 were 7.1% vs. 21.4% for NCGT2. Conclusions: Unexpected differences in OS can occur between patient cohorts recruited by study groups co-operating in international randomised trials. Higher rates of local recurrence and poorer survival were seen in NCTG 2. Failure to select or deliver appropriate local treatment modalities for ES may compromise chances of cure. No significant financial relationships to disclose.
The do-not-resuscitate order for terminal cancer patients in China mainland: A retrospective research.
Authors: Boyan Huang, Hui-ping Chen, Yaotiao Deng, Yu-qing Wang, Jie Zhang, Jie Liu, Yu Jiang
Journal: Journal of Clinical Oncology (2016)

e21515 Background: Under the influence of Chinese traditional culture, physicians often implement aggressive treatment on patients with terminal cancer although it is of no use in most cases. Recently, a signed Do-not-resuscitate (DNR) order, which means abandoning cardiopulmonary resuscitation when patients have a cardiac or respiratory arrest, became popular both in China (especially in Taiwan and Hong Kong) and abroad. This study aimed to estimate the status of DNR order for patients of cancer in China mainland. Methods: Retrospective reviews were performed. We screened all medical records from a large-scale tertiary teaching hospital in China for patients who died in oncology ward during the period from January 2010 to January 2015. The details of the DNR order forms were recorded. Results: A total of 365 medical records were reviewed, among which 292 records (80%) contained a signed DNR order. The median time of signing on the DNR order was one day prior to patient’s death. Most DNR orders (239/292,81.9%) were signed within 3 days prior to patient's death, half of which (120/239,50.2%) were just on the day of death. Only 2 patients signed on the DNR order by themselves, while the next of kin signed the majority of forms (290/292, 99.3%) as patient’s surrogate:135(46.2%) were patient’s spouse and 131(44.9%) were their adult offspring. Two hundreds and eighty seven patients(98.3%) with a DNR order had received critical condition notice (CCN) from hospital at least once. The median interval time between receiving the first CCN and signing on DNR order were 3 days. Only three forms of DNR order were signed before receiving the first CCN, 70%(201/287) were signed within one week after receiving CCN. Starting from the day of receiving the first CCN, the faster the disease progressed to death, the earlier the DNR orders were signed. The two time intervals were positively related(R = 0.925, R2= 0.856, P < 0.001). Conclusions: Based on our research, consent for a DNR order was common in China mainland. However, signing on a DNR order was rarely a decision of patients themselves. Usually the DNR decision was made when patients were already severely ill. Our results reflect the need for the improvement of end-of-life care in China mainland.
Trastuzumab prolonged administration: Safety and toxicity profile in heavily pre-treated patients
Authors: A. E. Tomadoni, R. C. Wainstein, M. N. Rondinón
Journal: Journal of Clinical Oncology (2006)

10742 Background: HER2 over-expression was found to be an independent prognostic predictor of overall survival and time to relapse in breast cancer patients. Trastuzumab binds to the extracellular domain of HER2 cell receptor, thereby inhibiting the growth of breast cancer cells that over-express HER2. Objective: examine safety and toxicity profile of trastuzumab prolonged treatment (&gt; 6 months) in heavily pre-treated HER2+ metastatic breast cancer patients. Methods: Between February 1999 and April 2005, 20 patients received weekly standard trastuzumab infusion until disease progression or serious adverse events. Population characteristics: median age: 46.6 years (30–65 years), ER+: 47.6%, PR+: 42.8%. Previous treatment: hormonotherapy: 12 patients (60%), two or more lines: 5 patients: (41.6%). All patients received previous chemotherapy: one line: 7 patients (35%), two lines: 10 (50%), three or more lines:3 (15%). Median trastuzumab treatment time was 11 months (6–36 months) Trastuzumab was administered as monotherapy in 5 patients (25%) and in combination in 15 patients (75%): 60% with docetaxel, 26.6% with paclitaxel, and 13.3 % with gemcitabine or vinorelbine Safety was primary trial end point, hence pre-treatment cardiac (baseline LVEF ≥55% by Echo or MUGA scan) and liver function assessment were required; and then, repeated each two months. Results: As regards cardiac adverse events, 2 patients (10%) receiving also docetaxel, developed supraventricular tachycardia reversible with 1 week treatment arrest. After 17 months, trastuzumab was discontinued in one of these two patients due to asymptomatic decrease in LVEF to 35 % (baseline LVEF:65%). An increase in transaninases (per 3ULN) was noted in one patient (5%) after 12 months of treatment. Liver function normalized after two weeks trastuzumab interruption. Allergic phenomena, as hot flashes or chills during first infusion was described in 3 patients (15%). In combination therapy, asthenia (20%), nausea (10%), anemia (10%), foot and hand syndrome (5%) and myalgia (5%) were observed. Conclusions: Prolonged tratuzumab administration in heavily pre-treated patients seems to be a safe approach with predictable profile and reversible toxicity with trastuzumab discontinuance and standard medical care. No significant financial relationships to disclose.
GW26-e1287 Aortic stiffness is associated with the central retinal arteriolar equivalent and retinal vascular fractal dimension in a population along the southeastern coast of China
Authors: lixian Zheng, Fan Lin, Pengli Zhu, Feng Huang, Qiaowei Li, Yin Yuan, Zhonghai Gao, Falin Chen
Journal: Journal of the American College of Cardiology (2015)
Outbreak of Salmonella Enteritidis linked to the consumption of frozen beefburgers received from a food bank and originating from Poland: northern France, December 2014 to April 2015
Authors: Gabrielle Jones, Nathalie Pihier, Caroline Vanbockstael, Simon Le Hello, Sabrina Cadel Six, Nelly Fournet, Nathalie Jourdan-da Silva
Journal: Eurosurveillance (2016)

A prolonged outbreak of Salmonella enterica serotype Enteritidis occurred in northern France between December 2014 and April 2015. Epidemiological investigations following the initial notification on 30 December 2014 of five cases of salmonellosis (two confirmed S. Enteritidis) in young children residing in the Somme department revealed that all cases frequented the same food bank A. Further epidemiological, microbiological and food trace-back investigations indicated frozen beefburgers as the source of the outbreak and the suspected lot originating from Poland was recalled on 22 January 2015. On 2 March 2015 a second notification of S. Enteritidis cases in the Somme reinitiated investigations that confirmed a link with food bank A and with consumption of frozen beefburgers from the same Polish producer. In the face of a possible persistent source of contamination, all frozen beefburgers distributed by food bank A and from the same origin were blocked on 3 March 2015. Microbiological analyses confirmed contamination by S. Enteritidis of frozen beefburgers from a second lot remaining in cases’ homes. A second recall was initiated on 6 March 2015 and all frozen beefburgers from the Polish producer remain blocked after analyses identified additional contaminated lots over several months of production.
Identification of a Plasmin-Interactive Site in the Factor VIII Light Chain Responsible for Proteolytic Cleavage at Lys36 in the A1 Domain.
Authors: Keiji Nogami, Midori Shima, Masahiro Takeyama, Kohei Tatsumi, Yuri Fujita, Evgueni L. Saenko, Ichiro Tanaka, Akira Yoshioka
Journal: Blood (2006)
Induction with New Drugs and Planned Autologous Followed by Non-Myeloablative Allogeneic Transplantation in Newly Diagnosed Myeloma.
Authors: Luisa Giaccone, Moreno Festuccia, Roberto Sorasio, Nicola Mordini, Fabrizio Carnevale Schianca, Francesca Patriarca, Marco Casini, Anna Paola Iori, Robin Foà, Mario Boccadoro, Benedetto Bruno
Journal: Blood (2009)
Viability of CD34+ Cells in Cryopreserved Cord Blood
Authors: Young-woo Eom, Seong Hyun Jeong, Jin-Hyuk Choi, Seok Yun Kang, Hyun Woo Lee, Mal Sook Yang, Hyo Eun Kim, In Keun Jang, Jong Eun Lee, Yeong Jin Kim, Hugh Chul Kim, Yoon Ho Hwang, Mi Sun Ahn, Joon Seong Park
Journal: Blood (2008)